Nemalkoholos steatohepatitis (NASH): Újabb hepatológiai szindróma?

Translated title of the contribution: Non-alcoholic steatohepatitis (NASH): A newer clinical entity?

Elemér Nemesánszky, F. Szalay, A. Pár

Research output: Contribution to journalArticle

Abstract

Non-alcoholic steatohepatitis (NASH) is an increasingly recognized clinico-pathologic condition that may progress to fibrosis and to end-stage liver disease as well. The pathological picture resembles that of alcohol-induced liver laesion, but NASH is a larger spectrum of disorders comprising nonalcoholic fatty liver that also includes hepatic steatosis. Distinction between the two clinico-pathological entities are important but relevant diagnosis can often be made only by 'case-by-case' basis. Most patients with NASH are obese, many have diabetes mellitus and hyperlipidaemia. Insulin resistance and oxidative stress have critical roles in the pathogenesis of NASH. Since laboratory features of NASH are not characteristic, liver biopsy remains the best diagnostic tool for confirming this hepatologic syndrome. There is no universally established medical therapy for all patients with NASH. Particularly those patients should be monitored closely and provide more careful metabolic controll, who show signs of marked inflammation and fibrosis in their liver biopsy. Behavioral changes and weight reduction are considered as main clues of the successfull therapy. Ursodeoxycholic acid, metadoxil and vitamin-E supplementation seems to help the liver to get rid of superfluous fat and improve laboratory parameters as well. In this review, the current literature regarding the nomenclature, clinical and histological spectrum, natural history, possibilities of diagnosis and of managment of NASH is discussed.

Original languageHungarian
Pages (from-to)3-10
Number of pages8
JournalOrvoskepzes
Volume78
Issue number1
Publication statusPublished - 2003

Fingerprint

Fatty Liver
Liver
Fibrosis
Biopsy
Ursodeoxycholic Acid
End Stage Liver Disease
Hyperlipidemias
Natural History
Vitamin E
Terminology
Insulin Resistance
Weight Loss
Diabetes Mellitus
Oxidative Stress
Fats
Alcohols
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nemalkoholos steatohepatitis (NASH) : Újabb hepatológiai szindróma? / Nemesánszky, Elemér; Szalay, F.; Pár, A.

In: Orvoskepzes, Vol. 78, No. 1, 2003, p. 3-10.

Research output: Contribution to journalArticle

@article{a613a56801a94374a86c19059ef09a84,
title = "Nemalkoholos steatohepatitis (NASH): {\'U}jabb hepatol{\'o}giai szindr{\'o}ma?",
abstract = "Non-alcoholic steatohepatitis (NASH) is an increasingly recognized clinico-pathologic condition that may progress to fibrosis and to end-stage liver disease as well. The pathological picture resembles that of alcohol-induced liver laesion, but NASH is a larger spectrum of disorders comprising nonalcoholic fatty liver that also includes hepatic steatosis. Distinction between the two clinico-pathological entities are important but relevant diagnosis can often be made only by 'case-by-case' basis. Most patients with NASH are obese, many have diabetes mellitus and hyperlipidaemia. Insulin resistance and oxidative stress have critical roles in the pathogenesis of NASH. Since laboratory features of NASH are not characteristic, liver biopsy remains the best diagnostic tool for confirming this hepatologic syndrome. There is no universally established medical therapy for all patients with NASH. Particularly those patients should be monitored closely and provide more careful metabolic controll, who show signs of marked inflammation and fibrosis in their liver biopsy. Behavioral changes and weight reduction are considered as main clues of the successfull therapy. Ursodeoxycholic acid, metadoxil and vitamin-E supplementation seems to help the liver to get rid of superfluous fat and improve laboratory parameters as well. In this review, the current literature regarding the nomenclature, clinical and histological spectrum, natural history, possibilities of diagnosis and of managment of NASH is discussed.",
keywords = "NASH diagnosis and therapy, Steatohepatitis, Steatosis",
author = "Elem{\'e}r Nemes{\'a}nszky and F. Szalay and A. P{\'a}r",
year = "2003",
language = "Hungarian",
volume = "78",
pages = "3--10",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "1",

}

TY - JOUR

T1 - Nemalkoholos steatohepatitis (NASH)

T2 - Újabb hepatológiai szindróma?

AU - Nemesánszky, Elemér

AU - Szalay, F.

AU - Pár, A.

PY - 2003

Y1 - 2003

N2 - Non-alcoholic steatohepatitis (NASH) is an increasingly recognized clinico-pathologic condition that may progress to fibrosis and to end-stage liver disease as well. The pathological picture resembles that of alcohol-induced liver laesion, but NASH is a larger spectrum of disorders comprising nonalcoholic fatty liver that also includes hepatic steatosis. Distinction between the two clinico-pathological entities are important but relevant diagnosis can often be made only by 'case-by-case' basis. Most patients with NASH are obese, many have diabetes mellitus and hyperlipidaemia. Insulin resistance and oxidative stress have critical roles in the pathogenesis of NASH. Since laboratory features of NASH are not characteristic, liver biopsy remains the best diagnostic tool for confirming this hepatologic syndrome. There is no universally established medical therapy for all patients with NASH. Particularly those patients should be monitored closely and provide more careful metabolic controll, who show signs of marked inflammation and fibrosis in their liver biopsy. Behavioral changes and weight reduction are considered as main clues of the successfull therapy. Ursodeoxycholic acid, metadoxil and vitamin-E supplementation seems to help the liver to get rid of superfluous fat and improve laboratory parameters as well. In this review, the current literature regarding the nomenclature, clinical and histological spectrum, natural history, possibilities of diagnosis and of managment of NASH is discussed.

AB - Non-alcoholic steatohepatitis (NASH) is an increasingly recognized clinico-pathologic condition that may progress to fibrosis and to end-stage liver disease as well. The pathological picture resembles that of alcohol-induced liver laesion, but NASH is a larger spectrum of disorders comprising nonalcoholic fatty liver that also includes hepatic steatosis. Distinction between the two clinico-pathological entities are important but relevant diagnosis can often be made only by 'case-by-case' basis. Most patients with NASH are obese, many have diabetes mellitus and hyperlipidaemia. Insulin resistance and oxidative stress have critical roles in the pathogenesis of NASH. Since laboratory features of NASH are not characteristic, liver biopsy remains the best diagnostic tool for confirming this hepatologic syndrome. There is no universally established medical therapy for all patients with NASH. Particularly those patients should be monitored closely and provide more careful metabolic controll, who show signs of marked inflammation and fibrosis in their liver biopsy. Behavioral changes and weight reduction are considered as main clues of the successfull therapy. Ursodeoxycholic acid, metadoxil and vitamin-E supplementation seems to help the liver to get rid of superfluous fat and improve laboratory parameters as well. In this review, the current literature regarding the nomenclature, clinical and histological spectrum, natural history, possibilities of diagnosis and of managment of NASH is discussed.

KW - NASH diagnosis and therapy

KW - Steatohepatitis

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=38549161545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549161545&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:38549161545

VL - 78

SP - 3

EP - 10

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 1

ER -